Dr Elaina Maginn received her PhD for work investigating novel therapeutic approaches for chronic B-cell malignancies. Subsequently, she joined the Division of Cancer, to investigate and develop new strategies for treating pancreatic cancer, with particular focus on identifying how DNA damage response pathways may be targeted for therapeutic gain. She was also involved in developing these strategies for ovarian cancer.
et al., 2019, Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-2-regulated apoptosis in pancreatic cancer cells, Cancer Biology and Therapy, Vol:20, ISSN:1555-8576, Pages:21-30
Dungl DA, Maginn EN, Stronach EA, 2015, Preventing Damage Limitation: Targeting DNA-PKcs and DNA Double-Strand Break Repair Pathways for Ovarian Cancer Therapy., Frontiers in Oncology, Vol:5, ISSN:2234-943X
et al., 2014, Opportunities for translation: Targeting DNA repair pathways in pancreatic cancer, Biochimica Et Biophysica Acta-reviews on Cancer, Vol:1846, ISSN:0304-419X, Pages:45-54
et al., 2013, The microtubule targeting agent PBOX-15 inhibits integrin-mediated cell adhesion and induces apoptosis in acute lymphoblastic leukaemia cells, International Journal of Oncology, Vol:42, ISSN:1019-6439, Pages:239-246
et al., 2011, DNA-PK Mediates AKT Activation and Apoptosis Inhibition in Clinically Acquired Platinum Resistance, Neoplasia, Vol:13, ISSN:1476-5586, Pages:1069-U114